文献速递系统性红斑狼疮

韩国多中心回顾性研究:SLE相关肺动脉高压不良结局的临床、血清学及血流动力学因素

Clinical, serological and haemodynamic factors associated with poor outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension: a multicentre retrospective study from Korea.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该多中心回顾性研究纳入68例经右心导管确诊的SLE相关肺动脉高压(SLE-PAH)患者,35例(51.3%)发生复合不良结局。多因素分析显示,升高的平均肺动脉压(mPAP)、较高的SLEDAI评分及联合PAH治疗是不良结局的独立预测因素。

要点

  • mPAP升高、SLEDAI评分高及联合PAH治疗与SLE-PAH不良结局独立相关。
  • 超过半数(51.3%)SLE-PAH患者发生复合不良结局。
  • 需重视全面血流动力学评估及狼疮活动度的管理。

核心结论

  • 升高的mPAP、活动性狼疮及联合PAH治疗与SLE-PAH患者不良结局独立相关。

研究设计与样本

  • 多中心回顾性研究,纳入8家三级中心经右心导管确诊的68例SLE-PAH患者。
  • 收集基线人口学、临床、实验室及血流动力学数据,以及SLEDAI评分和PAH相关参数。
  • 主要终点为复合结局:PAH症状加重需升级治疗、肺移植、死亡或住院。
  • 采用单因素和多因素logistic回归分析识别独立预测因素。

主要发现

  • 68例患者中35例(51.3%)发生复合结局。
  • 发生复合结局者基线6分钟步行距离更短(P=0.024),三尖瓣反流速度更高(P=0.032),右心室收缩压更高(P=0.035),mPAP更高(P<0.001),医生整体评估均分更高(P=0.001),SLEDAI均分更高(P=0.005),联合PAH治疗使用更频繁(P=0.033)。
  • 多因素分析中,mPAP升高(OR 5.401;95%CI 1.129-25.837,P=0.035)、SLEDAI较高(OR 5.495;95%CI 1.041-29.012,P=0.045)及联合PAH治疗(OR 1.695;95%CI 1.015-3.267,P=0.017)为复合结局的独立预测因素。

关键数值与推荐

  • 复合不良结局定义为PAH症状加重需升级治疗、肺移植、死亡或住院。
  • 多因素分析中mPAP升高OR 5.401(95%CI 1.129-25.837,P=0.035)。
  • 多因素分析中SLEDAI较高OR 5.495(95%CI 1.041-29.012,P=0.045)。
  • 多因素分析中联合PAH治疗OR 1.695(95%CI 1.015-3.267,P=0.017)。

临床怎么用

  • 对SLE-PAH患者应进行全面血流动力学评估,包括mPAP等指标。
  • 应仔细管理狼疮活动度,SLEDAI较高提示不良结局风险增加。
  • 联合PAH治疗的使用与不良结局相关,需结合病情审慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify factors associated with adverse outcomes in Korean patients with systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) confirmed by right heart catheterization (RHC). METHODS: This multicentre retrospective study included 68 patients with SLE-PAH diagnosed by RHC at eight tertiary centres. Baseline demographic, clinical, laboratory and haemodynamic data were collected, along with SLE Disease Activity Index (SLEDAI) scores and PAH-related parameters. Primary endpoint was a composite outcome of worsening PAH symptoms requiring treatment escalation, lung transplantation, death or hospitalization. Univariable and multivariable logistic regression analyses were performed to identify independent predictors. RESULTS: Of 68 patients, 35 (51.3%) experienced composite outcomes. Compared with those without composite outcomes, patients with composite outcomes had significantly shorter baseline 6-min walk distances (P = 0.024), higher tricuspid regurgitation velocity (P = 0.032), higher right ventricular systolic pressure (P = 0.035), higher mean pulmonary arterial pressure (mPAP) (P < 0.001), higher mean physician global assessment scores (P = 0.001), higher mean SLEDAI scores (P = 0.005) and more frequent use of combination PAH therapy (P = 0.033). In multivariable analysis, elevated mPAP (odds ratio (OR) 5.401; 95% confidence interval (CI) 1.129-25.837, P = 0.035), higher SLEDAI (OR 5.495; 95% CI 1.041-29.012, P = 0.045) and combination PAH therapy (OR 1.695; 95% CI 1.015-3.267, P = 0.017) remained independent predictors of composite outcomes. CONCLUSIONS: Elevated mPAP, active lupus and use of combination PAH therapy were independently associated with poor outcomes in SLE-PAH, highlighting the relevance of comprehensive haemodynamic assessment and careful management of lupus activity.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kang JH, Yoon J, Song JJ, et al. Clinical, serological and haemodynamic factors associated with poor outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension: a multicentre retrospective study from Korea. Rheumatology (Oxford). 2026. PMID: 41912438. doi:10.1093/rheumatology/keag148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。